Drugs / T0001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02481180 | Jul 2015 → Nov 2017 | rheumatoid arthritis | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT02291471 | Oct 2014 → Feb 2015 | rheumatic disorder | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T0001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02291471 ↗ |
| Action | Inhibit | “T0001 can inhibit the binding of soluble TNFα (sTNFα) or membrane-bound TNFα (mTNFα) to TNF receptors.” PMID 28542350 ↗ May 2017 |
| Modality | Protein / enzyme biologic | “T0001 is a recombinant human TNFR-Fc fusion protein mutant” PMID 28542350 ↗ May 2017 |
| Route | Subcutaneous | “injection (SC) T0001 15mg weekly for 12 weeks” NCT02481180 ↗ |
| Target | TNF | “T0001 can inhibit the binding of soluble TNFα (sTNFα) or membrane-bound TNFα (mTNFα) to TNF receptors.” PMID 28542350 ↗ May 2017 |